Efficacy and Safety of Recombinant Asparaginase in Infants (<1 Year) With Previously Untreated Acute Lymphoblastic Leukaemia - Phase II Clinical Trial
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
number of patients with hypersensitivity reactions to rASNase
within 2 months
Yes
Rob Pieters, MD
Principal Investigator
Erasmus MC-Sophia Children's Hospital
Germany: Federal Institute for Drugs and Medical Devices
MC-ASP.6/INF
NCT00983138
July 2009
February 2011
Name | Location |
---|